Ascendis Pharma (ASND) to Offer $400M in Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Ascendis Pharma (ASND) Prices 2.5M ADS Offering at $160/sh
September 2, 2021 5:23 AM EDTAscendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients lives, today announced the pricing of its underwritten public offering of 2,500,000 American Depositary Shares (ADSs), each of which represents one ordinary share of Ascendis, at a price to the public of $160.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 7, 2021 subject to customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to... More
